While the market becomes increasingly crowded with innovator drugs, pharma is finding it harder to recoup development costs. Join our panel of experts to understand how we should build innovative, cost-effective payment models based on 21st-century definitions of value. With Tamar Thompson, Director Federal Agency Payment (Bristol-Myers Squibb), Jennifer Hinkel, Partner (McGivney Global Advisors), hosted by Ulrich Neumann, US Managing Director, eyeforpharma)